Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 150 results for multiple sclerosis

  1. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.

  2. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

  3. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.

  4. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in ...

  5. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...

  6. Cladribine for treating relapsing multiple sclerosis ID6263

    In development [GID-TA11293] Expected publication date: TBC

  7. Nirmatrelvir plus ritonavir for treating COVID-19 (Partial Rapid Review of TA878) [ID6262]

    In development [GID-TA11324] Expected publication date: 13 March 2024

  8. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

  9. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

  10. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  11. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis (IPG640)

    Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.

  12. Supporting people with multiple sclerosis, who have limited mobility or are full-time wheelchair users, to remain physically active with the use of Oswestry standing frames

    with moderate to severe multiple sclerosis (MS) remain physically active. It supports CG186 and QS 108 statement 4: 'Adults...

  13. Glatiramer acetate depot for multiple sclerosis [TS ID 10620]

      Status ...

  14. Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845

    Awaiting development [GID-TA11333] Expected publication date: TBC

  15. Ublituximab for treating relapsing–remitting multiple sclerosis TS ID 11795

    Awaiting development [GID-TA11268] Expected publication date: TBC